MICTORYL PEDIATRIC TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

PROPIVERINE HYDROCHLORIDE

Предлага се от:

DUCHESNAY INC

АТС код:

G04BD06

INN (Международно Name):

PROPIVERINE

дозиране:

5MG

Лекарствена форма:

TABLET

Композиция:

PROPIVERINE HYDROCHLORIDE 5MG

Начин на приложение:

ORAL

Броя в опаковка:

28

Вид предписание :

Prescription

Терапевтична област:

Antimuscarinics

Каталог на резюме:

Active ingredient group (AIG) number: 0158750003; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2017-01-05

Данни за продукта

_Mictoryl_
_®_
_/Mictoryl_
_®_
_ Pediatric Product Monograph _
_Page 1 of 39 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
MICTORYL
®
Propiverine hydrochloride modified-release capsules
30 mg and 45 mg
Pr
MICTORYL
® PEDIATRIC
Propiverine hydrochloride tablets
5 mg
ATC Code: G04BD06
Anticholinergic and antispasmodic agent
Duchesnay Inc.
950, boul. Michèle-Bohec
Blainville, Québec
Canada, J7C 5E2
Date of Revision:
January 15, 2018
Submission Control No: 210208
_ _
_Mictoryl_
_®_
_/Mictoryl_
_® _
_Pediatric Product Monograph _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................16
SPECIAL HANDLING INSTRUCTIONS
.......................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................16
PART II: SCIENTIFIC INFORMATION
........